The administration of steroid and non-steroid anti-inflammatory drugs (NSAIDs) to cancer patients may inhibit the levels of peripheral blood COX-2 released by tumors, resulting in a change in serum levels [14,15]. The gene discussed is PTGS2; the disease is cancer.